107 filings
Page 3 of 6
S-8
5ulbs
30 Mar 23
Registration of securities for employees
9:00am
8-K
35l8sqf62l3lla
30 Mar 23
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
7:19am
8-K
bv522h ms6rt5hli
27 Jan 23
Entry into a Material Definitive Agreement
5:14pm
424B5
jjkwiag87yuk
27 Jan 23
Prospectus supplement for primary offering
5:04pm
8-K
wc0viau tqye
26 Jan 23
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody, being developed for solid tumors
11:28am
8-K
6lz8btep8q i5ar43hxq
23 Dec 22
Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
4:27pm
8-K
llufqnclk6m9ou
12 Dec 22
Regulation FD Disclosure
6:37am
8-K
ggua6v cq
10 Nov 22
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
7:04am
8-K
okl78zn
14 Oct 22
Departure of Directors or Certain Officers
7:00am
8-K
a8s6k wyd2cnyq
6 Oct 22
Other Events
5:06pm
8-K
o6ycjqcj a4rcwj
12 Sep 22
Regulation FD Disclosure
7:16am
8-K
9aztezafvvb9lo445b
10 Aug 22
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2022; Provides Program Update for ZF874
12:00am
EFFECT
8jn2dcxp 5v
13 Jul 22
Notice of effectiveness
12:15am
8-K
gcicxbe59 b4k276cadc
8 Jul 22
Departure of Directors or Certain Officers
4:32pm
S-3
2wr v34c29
1 Jul 22
Shelf registration
4:06pm
S-8
he7pd7k
1 Jul 22
Registration of securities for employees
4:06pm
8-K
ekr83nkf30quqfdi
1 Jul 22
Centessa Pharmaceuticals Announces Appointment of Dr. Mathias Hukkelhoven
8:45am